Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases.
Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment - a fully human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials, including a humanized IgG4 specific for IL-17 (ixekizumab) and a fully human antibody that targets the IL-17 receptor A (brodalumab).
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
Agnieszka
A
Wasilewska
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
Marta
M
Winiarska
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
Małgorzata
M
Olszewska
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
Lidia
L
Rudnicka
alopecia areata; fynomer; lichen planus; pemphigoid; pemphigus